Syntimmune Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.2B
Syntimmune General Information
Description
Operator is a clinical-stage biotechnology platform designed to develop differentiated drug candidates in a wide range of autoimmune diseases. The company's platform leverages a deep understanding of FcRn biology to develop transformative therapies for patients with autoimmune diseases, enabling physicians to get humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes to improve treatment in a number of rare IgG-mediated diseases.
Contact Information
Website
www.syntimmune.comCorporate Office
- 116 Huntington Avenue
- Suite 301
- Boston, MA 02116
- United States
Corporate Office
- 116 Huntington Avenue
- Suite 301
- Boston, MA 02116
- United States
Syntimmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 02-Nov-2018 | $1.2B | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B) | 21-Jun-2017 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 22-Mar-2016 | $26M | $28M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 01-Jan-2014 | $2M | $2M | Completed | Startup |
Syntimmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Syntimmune Comparisons
Industry
Financing
Details
Syntimmune Competitors (99)
One of Syntimmune’s 99 competitors is Actym Therapeutics, a Venture Capital-Backed company based in Berkeley, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Actym Therapeutics | Venture Capital-Backed | Berkeley, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Byondis | Corporation | Nijmegen, Netherlands | ||||
| Centrose | Venture Capital-Backed | Madison, WI |
Syntimmune Patents
Syntimmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017257680-A1 | Humanized affinity matured anti-fcrn antibodies | Inactive | 25-Apr-2016 | ||
| CA-3024421-A1 | Humanized affinity matured anti-fcrn antibodies | Inactive | 25-Apr-2016 | ||
| EP-3448429-A1 | Humanized affinity matured anti-fcrn antibodies | Active | 25-Apr-2016 | ||
| EP-3448429-A4 | Humanized affinity matured anti-fcrn antibodies | Active | 25-Apr-2016 | ||
| EP-3448429-B1 | Humanized affinity matured anti-fcrn antibodies | Active | 25-Apr-2016 | C07K16/28 |
Syntimmune Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apple Tree Partners (ATP) | Venture Capital | Minority | ||
| Baxalta Ventures | Corporate Venture Capital | Minority | ||
| FMB Research | Corporation | Minority | ||
| Mass General Brigham Innovation | Accelerator/Incubator | Minority | ||
| Mass General Brigham Ventures | Venture Capital | Minority |
Syntimmune FAQs
-
When was Syntimmune founded?
Syntimmune was founded in 2013.
-
Where is Syntimmune headquartered?
Syntimmune is headquartered in Boston, MA.
-
What industry is Syntimmune in?
Syntimmune’s primary industry is Drug Discovery.
-
Is Syntimmune a private or public company?
Syntimmune is a Private company.
-
What is the current valuation of Syntimmune?
The current valuation of Syntimmune is .
-
What is Syntimmune’s current revenue?
The current revenue for Syntimmune is .
-
How much funding has Syntimmune raised over time?
Syntimmune has raised $78M.
-
Who are Syntimmune’s investors?
Apple Tree Partners (ATP), Baxalta Ventures, FMB Research, Mass General Brigham Innovation, and Mass General Brigham Ventures are 5 of 6 investors who have invested in Syntimmune.
-
Who are Syntimmune’s competitors?
Actym Therapeutics, Adimab, CytomX Therapeutics, Byondis, and Centrose are some of the 99 competitors of Syntimmune.
-
When was Syntimmune acquired?
Syntimmune was acquired on 02-Nov-2018.
-
Who acquired Syntimmune?
Syntimmune was acquired by Alexion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process